@article{b75a4685d9374457bca9b512da6b261f,
title = "American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action",
abstract = "Objective: Given the increasing evidence that obesity increases the risk of developing and dying from malignancy, the American Society of Clinical Oncology (ASCO) launched an Obesity Initiative in 2013 that was designed to increase awareness among oncology providers and the general public of the relationship between obesity and cancer and to promote research in this area. Recognizing that the type of societal change required to impact the obesity epidemic will require a broad-based effort, ASCO hosted the “Summit on Addressing Obesity through Multidisciplinary Collaboration” in 2016. Methods: This meeting was held to review current challenges in addressing obesity within the respective health care provider communities and to identify priorities that would most benefit from a collective and cross-disciplinary approach. Results: Efforts focused on four key areas: provider education and training; public education and activation; research; and policy and advocacy. Summit attendees discussed current challenges in addressing obesity within their provider communities and identified priorities that would most benefit from multidisciplinary collaboration. Conclusions: A synopsis of recommendations to facilitate future collaboration, as well as examples of ongoing cooperative efforts, provides a blueprint for multidisciplinary provider collaboration focused on obesity prevention and treatment.",
author = "Ligibel, {Jennifer A.} and Alfano, {Catherine M.} and Hershman, {Dawn L.} and Merrill, {Janette K.} and Karen Basen-Engquist and Bloomgarden, {Zachary T.} and Wendy Demark-Wahnefried and Suzanne Dixon and Hassink, {Sandra G.} and Jakicic, {John M.} and Morton, {John Maga{\~n}a} and Okwuosa, {Tochi M.} and Powell-Wiley, {Tiffany M.} and Rothberg, {Amy E.} and Mark Stephens and Streett, {Sarah E.} and Wild, {Robert A.} and Westman, {Eric A.} and Williams, {Ronald J.} and Wollins, {Dana S.} and Hudis, {Clifford A.}",
note = "Funding Information: Funding agencies: The American Society of Clinical Oncology hosted the in-person meeting detailed in this manuscript and assumed costs of travel, lodging, and meals for all participants. TMPW is funded by the Division of Intramural Research of the National Heart, Lung, and Blood Institute of the National Institutes of Health. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the US Department of Health and Human Services. Disclosure: The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. ZTB: Stock or other ownership (Allergen, Pfizer, Zimmer Biomet, Novartis); Honoraria (Merck, Astra Zeneca, Johnson & Johnson); Consulting or advisory role (Astra Zeneca, Johnson & Johnson, Merck, Intarcia, Novartis); Speakers{\textquoteright} Bureau (Merck, Astra Zeneca, Johnson & Johnson). SD: Employment (Abbott Nutrition); Honoraria (Abbott Nutrition); Speakers{\textquoteright} Bureau (Abbott Nutrition); Travel, accommodations, expenses (Abbott Nutrition). JMJ: Consulting or advisory role (Weight Watchers International); Research funding (Weight Watchers International). AER: Consulting or advisory role (Nestl{\'e} Optifast Division). MS: Other relationships (5-Minute Clinical Consult, PriMed). RAW: Consulting or advisory role (Massachusetts General Hospital). EAW: Consulting or advisory role (Vivus); Speakers{\textquoteright} Bureau (Vivus). RJW: Consulting or advisory role (HighMark Insurance Company). CAH: Consulting or advisory role (Pfizer, Lilly, Merck, Novartis, Roche/Genentech); Other relationship (Breast Cancer Research Foundation). The other authors declare no conflicts of interest. Received: 9 June 2017; Accepted: 9 August 2017; Published online in Wiley Online Library. doi:10.1002/oby.21987 Funding Information: Funding for the project represented an additional challenge. Once approved, the trial would be conducted through the National Clinical Trials Network and NCI Community Oncology Research Program infrastructure; however, funding for behavioral interventions is not available through this mechanism. Funding ultimately was assembled through a joint effort of three NCI groups—the Division of Cancer Prevention, the Division of Cancer Control and Population Sciences, and the Cancer Therapy Evaluation Program—with additional support from the Susan G. Komen Foundation, the American Cancer Society, and in-kind product donation to support the life-style intervention from corporate sponsors such as Fitbit and Nestl{\'e} Health Sciences. Publisher Copyright: {\textcopyright} 2017 The Obesity Society",
year = "2017",
month = nov,
doi = "10.1002/oby.21987",
language = "English (US)",
volume = "25",
pages = "S34--S39",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
}